Theravance Biopharma, Inc. (TBPH) Stock Analysis
Momentum Cont setup
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $16.93 — A.R:R is negative (-3.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2).
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine... Read more
Sell if holding. Analyst target reached at $16.93 — A.R:R is negative (-3.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2). Chart setup: Trend continuation, RSI 58, MACD bullish. Score 5.6/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 39d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — Theravance Biopharma, Inc.
Latest news
- NEWS Jones Trading Downgrades Theravance Biopharma to Hold — benzinga Jun 29, 2026 negative
- NEWS BTIG Downgrades Theravance Biopharma to Neutral — benzinga Jun 29, 2026 negative
- NEWS Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition — benzinga Jun 29, 2026 positive
Generated 2026-07-05T07:10:32Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $16.93 — A.R:R is negative (-3.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2). Chart setup: Trend continuation, RSI 58, MACD bullish. Prior stop was $16.15. Score 5.6/10, moderate confidence.
Take-profit target: $17.39 (+2.7% upside). Prior stop was $16.15. Stop-loss: $16.15.
Analyst target reached - limited upside remaining; Consecutive earnings misses (2); Value-trap signals (2/5): Margin compression (op margin -33.1%), Material insider selling (3 sells, 0.02% of cap).
Theravance Biopharma, Inc. trades at a P/E of 7.6 (forward 13.5). TrendMatrix value score: 6.3/10. Verdict: Sell.
12 analysts cover TBPH with a consensus score of 3.9/5. Average price target: $17.
What does Theravance Biopharma, Inc. do?Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It...
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.